Vietnam Liver Cancer Therapeutics Market Report 2022 to 2030

Vietnam Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam liver cancer therapeutics market will reach a value of $54.4 Mn from $14.65 Mn in 2022, growing at a CAGR of 17.8% during 2022-30. Liver cancer therapeutics in Vietnam are dominated by a few domestic pharmaceutical companies such as OPC Pharmaceutical, Vimedimex Medi-Pharma, and Hau Giang Pharmaceutical. The liver cancer therapeutics market in Vietnam is segmented into different types of cancer and different therapy types. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10VNPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Vietnam liver cancer therapeutics market will reach a value of $54.4 Mn from $14.65 Mn in 2022, growing at a CAGR of 17.8% during 2022-30.

Vietnam is a low-middle-income, developing country located in Southeastern Asia bordering the Gulf of Thailand, the Gulf of Tonkin, and the South China Sea. According to the latest WHO data published in 2020 Liver Cancer Deaths in Viet Nam reached 24,995 or 3.65% of total deaths. The age-adjusted death rate is 24.37 per 100,000 of the population ranking Vietnam 7^th in the world.

Hepatitis B and C have the greatest rates of infection among viruses in Vietnam, with 7.8 Mn and 1 Mn chronically infected people, respectively (according to the Ministry of Health of Vietnam, in 2022). Vietnam's government spent 4.7 % of its GDP on healthcare in 2020.

vietnam liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

Liver cancer due to alcohol drinking was responsible for 50% of gastrointestinal malignancies. With an estimated 25,000 new cases diagnosed each year, liver cancer is one of the top causes of cancer-related fatalities in Vietnam. The rate of liver cancer is especially high in areas where hepatitis B and C are prevalent, as is the situation in much of Vietnam. Vietnam's economy is prospering, with one of the region's strongest growth rates. Vietnam's enormous labour pool and low labour costs make company expansion easier.

Market Restraints

There are few therapeutic choices for liver cancer, especially for patients with advanced illnesses. This may limit the efficacy of liver cancer therapies as well as market growth. Liver cancer therapies can be costly, and the high expense of therapy may prevent some patients from receiving them. Shortcomings in the business climate in Vietnam, fueled by worries about data transparency and corruption perceptions, can make doing business difficult.

Competitive Landscape

Key Players

Hau Giang Pharmaceutical: Hau Giang is a Vietnamese pharmaceutical company that specializes in the development and production of generic drugs, including oncology drugs. Their portfolio includes drugs such as Doxorubicin Hau Giang, Paclitaxel Hau Giang, and Vinorelbine Hau Giang
Vimedimex Medi-Pharma: Vimedimex is a Vietnamese pharmaceutical company that develops and manufactures drugs for various diseases, including liver cancer
Vietnam Pharmaceutical Corporation (Vinapharm): Vinapharm is a state-owned pharmaceutical company in Vietnam that specializes in the production and distribution of pharmaceutical products, including oncology drugs
OPC Pharmaceutical
Traphaco

Recent Notable Updates

May 2022: The Ministry of Health's Medical Service Administration and biotechnology business Roche Vietnam signed an agreement on May 10 to execute a cooperative liver cancer management programme in 2022-2023. The program's goal is to raise awareness and capability for the diagnosis, treatment, prediction, and management of liver cancer.

Healthcare Policies and Reimbursement Scenarios

The Ministry of Health in Vietnam is the regulatory authority in charge of approving liver cancer medicines (MOH). The MOH oversees ensuring that medications and medical equipment used in Vietnam are safe and effective. Once a medicine is licenced for use in Vietnam, it may be reimbursed through the Health Insurance Agency (HIA) programme. The HIA programme covers a wide range of medical services and pharmaceuticals, including those used to treat liver cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.